Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Vixarelimab · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Vixarelimab | EXPERIMENTAL | Participants will receive subcutaneous (SC) injections of vixarelimab during the treatment period. |
| Name | Type | Description |
|---|---|---|
| Vixarelimab | DRUG | Vixarelimab will be administered as per the schedule specified. |
Inclusion Criteria: * Diagnosis of UC established at least 3 months * Moderately to severely active UC * Participants must meet criteria for either advanced therapy failure or conventional therapy failure Exclusion Criteria: * Diagnosis of Crohn's disease or indeterminate colitis * Suspicion of i...
Vixarelimab is an investigational antibody being studied for the treatment of moderate to severe active ulcerative colitis. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities. The drug is being evaluated in a clinical trial to assess its activity and safety in participants with this condition.
Vixarelimab is a monoclonal antibody, indicated by its -mab suffix, designed to target a specific molecular pathway involved in inflammation. As an antibody-based therapy, it is intended to modulate immune responses implicated in ulcerative colitis. The precise molecular target is not disclosed in the available information.
Vixarelimab is being developed by Roche Holding AG, a multinational healthcare company traded under the ticker symbol RHHBY. Roche is conducting clinical research on this investigational drug for moderate to severe ulcerative colitis, with the drug currently in Phase 1 development.
Vixarelimab is in Phase 1 clinical development for moderate to severe ulcerative colitis. It is an investigational drug, meaning it has not been approved by the FDA or other regulatory agencies. The ongoing Phase 1 trial is active but not recruiting participants, with a planned enrollment of 24 individuals.
Vixarelimab is being evaluated in a single Phase 1 clinical trial registered as NCT06693908. This study, titled 'A Study to Evaluate the Activity, and Safety of Vixarelimab in Participants With Moderate to Severe Active Ulcerative Colitis,' is active but not recruiting. It is an uncontrolled, open-label trial enrolling 24 participants in Germany.
No alternative names for Vixarelimab have been identified. The drug is known by its single name, Vixarelimab, and is being developed by Roche Holding AG. It is a distinct investigational antibody therapy for moderate to severe ulcerative colitis, currently in Phase 1 clinical trials.